Table 1.
The clinical background of patient specimens.
| Characteristic | All | BMMNC RNA-seq | CD138 + cell RNA-seq |
|---|---|---|---|
| (n = 49) | (n = 29) | (n = 26) | |
| Median age, year (range) | 71 (37–86) | 73 (49–86) | 72 (49–86) |
| Age > 75 years | 18 (36.7) | 12 (41.4) | 10 (38.5) |
| Age ≦75 years | 31 (63.3) | 27 (93.1) | 16 (61.5) |
| Male | 25 (51.0) | 14 (48.3) | 12 (46.2) |
| Female | 24 (49.0) | 15 (51.7) | 14 (53.8) |
| ISS stage | |||
| I | 9 (18.4) | 4 (13.8) | 3 (11.5) |
| II | 27 (55.1) | 18 (62.1) | 16 (61.5) |
| III | 13 (26.5) | 7 (24.1) | 7 (26.9) |
| High-risk cytogenetics* | 17 (34.7) | 13 (44.8) | 13 (50.0) |
| Median no. of prior anti-MM regimens, n (range) | 1.00 (0–8) | 1.00 (0–7) | 1.50 (0–7) |
| Prior anti-MM regimens | |||
| ND | 17 (34.7) | 11 (37.9) | 10 (38.5) |
| 1 | 8 (16.3) | 5 (17.2) | 3 (11.5) |
| 2 | 6 (12.2) | 5 (17.2) | 4 (15.4) |
| 3 + | 18 (36.7) | 8 (27.6) | 9 (34.6) |
| Prior therapy | |||
| PIs exposed | 31 (63.3) | 17 (58.6) | 15 (57.7) |
| IMiDs exposed | 23 (46.9) | 12 (41.4) | 12 (46.2) |
| Anti-CD38 mAb exposed | 21 (42.9) | 12 (41.4) | 12 (46.2) |
| BCMA-CART exposed | 3 (6.1) | 3 (10.3) | 3 (11.5) |
| Bortezomib exposed | 31 (63.3) | 17 (58.6) | 15 (57.7) |
| Lenalidmide exposed | 23 (46.9) | 12 (41.4) | 12 (46.2) |
| Pomalidmide exposed | 11 (22.4) | 7 (24.1) | 6 (23.1) |
| Daratuzumab exposed | 20 (40.8) | 11 (37.9) | 11 (42.3) |
| Double class† | 22 (44.9) | 11 (37.9) | 11 (42.3) |
| Triple class‡ | 18 (36.7) | 9 (31.0) | 9 (34.6) |
| Prior autologous SCT | 15 (30.6) | 7 (24.1) | 7 (26.9) |
| Refractory status | |||
| Double class refractory | 15 (30.6) | 8 (27.6) | 8 (30.8) |
| Triple class refractory | 13 (26.5) | 7 (24.1) | 7 (26.9) |
Data are presented as unweighted number (percentage) of patients unless otherwise indicated.
*More than one chromosomal abnormalities t(4;14), t(14;16), t(14,20), del 17p, 1q gains.
†Double class: PIs plus IMiDs exposed.
‡Triple class: PIs, IMiDs and anti-CD38 Ab exposed.